Understand the source comparison
Peptides vs Exogenous GH: Clinical Outcomes Comparison
Mechanism of Action Stimulates endogenous pituitary GH secretion via GHRH and ghrelin receptor activation Direct exogenous replacement. Bypasses pituitary entirely Peptides preserve endogenous axis function; rhGH creates dependency through negative feedback su
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Mechanism of Action
- Stimulates endogenous pituitary GH secretion via GHRH and ghrelin receptor activation
- Direct exogenous replacement. Bypasses pituitary entirely
- Peptides preserve endogenous axis function; rhGH creates dependency through negative feedback suppression
- Serum GH Pattern
- Pulsatile secretion maintaining circadian rhythmicity (3-5 pulses/day)
- Supraphysiologic steady-state elevation for 12-18 hours post-injection
- Peptides replicate natural GH dynamics; rhGH produces non-physiologic flat peaks
- IGF-1 Increase
- 30-60% above baseline within 8-12 weeks at standard dosing
- 100-200% above baseline. Dose-dependent but often supraphysiologic
- rhGH produces larger IGF-1 elevations but increases risk of insulin resistance and edema
- Axis Suppression Risk
- Minimal. Hypothalamic-pituitary feedback remains intact
- Significant. Suppresses endogenous GH synthesis for months after cessation
- Stopping peptides restores baseline GH within days; rhGH cessation requires 3-6 month recovery
- Regulatory Classification
- Research peptides. Not FDA-approved for GH deficiency treatment
- FDA-approved for pediatric and adult GH deficiency (branded as Norditropin, Genotropin, etc.)
- rhGH has established clinical indication; peptides remain investigational
- Cost (Research Context)
- $150-$400/month for combination protocols (CJC-1295 + ipamorelin or MK-677)
- $500-$1500/month depending on dose and formulation
- Peptides offer 60-80% cost reduction vs branded rhGH